EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Continuous Subcutaneous Foslevodopa‐Foscarbidopa in Parkinson's Disease: A Mini‐Review of Current Scope and Future Outlook

Mickael Aubignat iD, Melissa Tir

Movement Disorders Clinical Practice · 2024-10 · 11 (10) · 1188-1194

DOI: 10.1002/mdc3.14161 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Movement Disorders Clinical Practice, online erschienen am 11.07.2024. Verfasst von Mickael Aubignat und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology and Movement Disorders, Amiens Picardie University Hospital, Amiens, France. Hauptthemen laut MEDLINE: Parkinson Disease, Carbidopa, Levodopa, Antiparkinson Agents. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by motor and non‐motor symptoms, primarily because of the impairment of dopaminergic neurons. Long‐term use of levodopa, the standard PD treatment, often results in fluctuating therapeutic effects and dyskinesia, necessitating alternative therapies.

Objectives

This review aims to synthesize current insights and clinical experiences with foslevodopa‐foscarbidopa, focusing on its pharmacokinetics, efficacy, and safety profile, to evaluate its potential in transforming PD therapy.

Methods

A systematic literature search was conducted up to November 2023 using databases PubMed, Web of Science, and Cochrane Library. The search yielded eight eligible articles, including pharmacological studies, case reports, observational studies, and controlled trials. No language restrictions were applied.

Results

Foslevodopa and foscarbidopa, as prodrugs of levodopa and carbidopa, exhibited excellent chemical stability and solubility, facilitating continuous subcutaneous infusion. Clinical trials demonstrated that these prodrugs maintain stable levodopa levels, thereby addressing the limitations of oral levodopa therapy. Phase 1 and 3 studies indicated significant improvements in motor function and quality of life in advanced PD patients. However, a higher incidence of treatment‐emergent adverse events, mainly infusion site reactions, was observed compared to oral therapies.

Conclusions

Foslevodopa‐foscarbidopa emerges as a promising alternative for advanced PD treatment, offering sustained symptom control. Its efficacy in managing motor fluctuations and dyskinesia makes it a viable option in the PD therapeutic spectrum. Future research should focus on long‐term safety, economic impact, and broader accessibility. Foslevodopa‐foscarbidopa is now commercially distributed in many countries in Europe and in Japan.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Parkinson DiseaseCarbidopaLevodopaAntiparkinson AgentsDrug CombinationsHumansInfusions, SubcutaneousProdrugs

Stichwörter der Autor:innen

ABBV‐951Parkinson's diseasefluctuationsfoscarbidopafoslevodopa

Substanzen

CarbidopaLevodopaAntiparkinson AgentsDrug Combinationscarbidopa, levodopa drug combinationProdrugs

Autor:innen und Institutionen

  • Department of Neurology and Movement Disorders, Amiens Picardie University Hospital, Amiens, France.
  • Expert Center for Parkinson's Disease, Amiens Picardie University Hospital, Amiens, France.

ORCID-Profile: Mickael Aubignat

Zitieren

APA

Aubignat, M., & Tir, M. (2024). Continuous Subcutaneous Foslevodopa‐Foscarbidopa in Parkinson's Disease: A Mini‐Review of Current Scope and Future Outlook. Movement Disorders Clinical Practice, 11(10), 1188-1194. https://doi.org/10.1002/mdc3.14161

Vancouver

Aubignat M, Tir M. Continuous Subcutaneous Foslevodopa‐Foscarbidopa in Parkinson's Disease: A Mini‐Review of Current Scope and Future Outlook. Movement Disorders Clinical Practice. 2024;11(10):1188-1194. doi:10.1002/mdc3.14161

BibTeX
@article{Aubignat2024,
  author = {Aubignat, Mickael and Tir, Melissa},
  title = {Continuous Subcutaneous Foslevodopa‐Foscarbidopa in Parkinson's Disease: A Mini‐Review of Current Scope and Future Outlook},
  journal = {Movement Disorders Clinical Practice},
  year = {2024},
  volume = {11},
  number = {10},
  pages = {1188--1194},
  doi = {10.1002/mdc3.14161}
}
Kostenlos starten →